Can multiple myeloma become a curable disease

[1]  J. Besalduch,et al.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. , 2011, Blood.

[2]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[3]  B. Barlogie,et al.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. , 2010, Blood.

[4]  B. Barlogie,et al.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.

[5]  J. Bladé,et al.  Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. , 2010, Blood.

[6]  M. Boccadoro,et al.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Crowley,et al.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Richardson,et al.  How I treat multiple myeloma in younger patients. , 2009, Blood.

[10]  A. Órfão,et al.  The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. , 2009, Blood.

[11]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[12]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.

[13]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[14]  L. Escoda,et al.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Anderson,et al.  Individualizing treatment of patients with myeloma in the era of novel agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Salvatore,et al.  18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.

[17]  B. Barlogie,et al.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[19]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[20]  A. Órfão,et al.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. , 2002, Blood.

[21]  Marcos González,et al.  Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. , 2005, Haematologica.